PCRX241220P22500
- 4.97
- 0.000.00%
Pacira BioSciences Newsroom
US Manufacturing Index Rises To 43, Highest Since 2020
Express News | Pacira Biosciences Inc - No Serious Treatment-Emergent Adverse Events Reported
Express News | Pacira Biosciences Inc - Phase 1 Trial Shows Safety and Efficacy of Pcrx-201
Express News | Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of Pcrx-201 for Moderate to Severe Osteoarthritis of the Knee
Pacira BioSciences Insider Lowered Holding By 85% During Last Year
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
Pacira BioSciences Price Target Cut to $17.00/Share From $25.00 by Barclays
Pacira BioSciences Is Maintained at Equal-Weight by Barclays
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
Needham Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $22
Pacira BioSciences Analyst Ratings
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth
RBC Capital Adjusts Price Target on Pacira Biosciences to $16 From $15, Maintains Sector Perform Rating
H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $39
Express News | Pacira Biosciences Inc : Piper Sandler Raises Target Price to $12 From $11
Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript Summary
Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript
Pacira BioSciences | 10-Q: Q3 2024 Earnings Report
Pacira BioSciences | 8-K: Pacira BioSciences Reports Third Quarter 2024 Financial Results
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q3 Revenue $168.6M